Literature DB >> 20228261

IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression.

Tadashi Yoshida1, Laura Semprun-Prieto, Sergiy Sukhanov, Patrice Delafontaine.   

Abstract

Congestive heart failure is associated with activation of the renin-angiotensin system and skeletal muscle wasting. Angiotensin II (ANG II) has been shown to increase muscle proteolysis and decrease circulating and skeletal muscle IGF-1. We have shown previously that skeletal muscle-specific overexpression of IGF-1 prevents proteolysis and apoptosis induced by ANG II. These findings indicated that downregulation of IGF-1 signaling in skeletal muscle played an important role in the wasting effect of ANG II. However, the signaling pathways and mechanisms whereby IGF-1 prevents ANG II-induced skeletal muscle atrophy are unknown. Here we show ANG II-induced transcriptional regulation of two ubiquitin ligases atrogin-1 and muscle ring finger-1 (MuRF-1) that precedes the reduction of skeletal muscle IGF-1 expression, suggesting that activation of atrogin-1 and MuRF-1 is an initial mechanism leading to skeletal muscle atrophy in response to ANG II. IGF-1 overexpression in skeletal muscle prevented ANG II-induced skeletal muscle wasting and the expression of atrogin-1, but not MuRF-1. Dominant-negative Akt and constitutively active Foxo-1 blocked the ability of IGF-1 to prevent ANG II-mediated upregulation of atrogin-1 and skeletal muscle wasting. Our findings demonstrate that the ability of IGF-1 to prevent ANG II-induced skeletal muscle wasting is mediated via an Akt- and Foxo-1-dependent signaling pathway that results in inhibition of atrogin-1 but not MuRF-1 expression. These data suggest strongly that atrogin-1 plays a critical role in mechanisms of ANG II-induced wasting in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20228261      PMCID: PMC2867436          DOI: 10.1152/ajpheart.00146.2010

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  23 in total

Review 1.  PI3K/Akt: getting it right matters.

Authors:  T F Franke
Journal:  Oncogene       Date:  2008-10-27       Impact factor: 9.867

Review 2.  Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome.

Authors:  Adrian Iaina; Donald S Silverberg; Dov Wexler
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2005-02

Review 3.  Intracellular signaling during skeletal muscle atrophy.

Authors:  Susan C Kandarian; Robert W Jackman
Journal:  Muscle Nerve       Date:  2006-02       Impact factor: 3.217

4.  Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle.

Authors:  A Musarò; K McCullagh; A Paul; L Houghton; G Dobrowolny; M Molinaro; E R Barton; H L Sweeney; N Rosenthal
Journal:  Nat Genet       Date:  2001-02       Impact factor: 38.330

5.  The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP.

Authors:  Carsten Skurk; Henrike Maatz; Hyo-Soo Kim; Jiang Yang; Md Ruhul Abid; William C Aird; Kenneth Walsh
Journal:  J Biol Chem       Date:  2003-10-08       Impact factor: 5.157

6.  Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.

Authors:  Marco Sandri; Claudia Sandri; Alex Gilbert; Carsten Skurk; Elisa Calabria; Anne Picard; Kenneth Walsh; Stefano Schiaffino; Stewart H Lecker; Alfred L Goldberg
Journal:  Cell       Date:  2004-04-30       Impact factor: 41.582

Review 7.  Ubiquitin-protein ligases in muscle wasting: multiple parallel pathways?

Authors:  Stewart H Lecker
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2003-05       Impact factor: 4.294

8.  Role of Akt/GSK-3beta/beta-catenin transduction pathway in the muscle anti-atrophy action of insulin-like growth factor-I in glucocorticoid-treated rats.

Authors:  O Schakman; S Kalista; L Bertrand; P Lause; J Verniers; J M Ketelslegers; J P Thissen
Journal:  Endocrinology       Date:  2008-05-08       Impact factor: 4.736

9.  Effects of dimethyl sulfoxide and dexamethasone on mRNA expression of housekeeping genes in cultures of C2C12 myotubes.

Authors:  Masuhiro Nishimura; Takeshi Nikawa; Yuichi Kawano; Mitsuo Nakayama; Muneharu Ikeda
Journal:  Biochem Biophys Res Commun       Date:  2008-01-10       Impact factor: 3.575

10.  IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting.

Authors:  Liping Zhang; Jie Du; Zhaoyong Hu; Guofeng Han; Patrice Delafontaine; Gabriela Garcia; William E Mitch
Journal:  J Am Soc Nephrol       Date:  2009-01-21       Impact factor: 10.121

View more
  51 in total

1.  ERK and Akt signaling pathways function through parallel mechanisms to promote mTORC1 signaling.

Authors:  Jeremiah N Winter; Leonard S Jefferson; Scot R Kimball
Journal:  Am J Physiol Cell Physiol       Date:  2011-02-02       Impact factor: 4.249

Review 2.  Effects of exercise training on neurovascular control and skeletal myopathy in systolic heart failure.

Authors:  Carlos E Negrao; Holly R Middlekauff; Igor L Gomes-Santos; Ligia M Antunes-Correa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-13       Impact factor: 4.733

3.  Different effects of the deletion of angiotensin converting enzyme 2 and chronic activation of the renin-angiotensin system on muscle weakness in middle-aged mice.

Authors:  Hikari Takeshita; Koichi Yamamoto; Masaki Mogi; Satoko Nozato; Masatsugu Horiuchi; Hiromi Rakugi
Journal:  Hypertens Res       Date:  2019-12-19       Impact factor: 3.872

4.  THE RENIN-ANGIOTENSIN SYSTEM AND THE BIOLOGY OF SKELETAL MUSCLE: MECHANISMS OF MUSCLE WASTING IN CHRONIC DISEASE STATES.

Authors:  Patrice Delafontaine; Tadashi Yoshida
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

Review 5.  Skeletal muscle inflammation and atrophy in heart failure.

Authors:  Kory J Lavine; Oscar L Sierra
Journal:  Heart Fail Rev       Date:  2017-03       Impact factor: 4.214

Review 6.  Angiotensin II, oxidative stress and skeletal muscle wasting.

Authors:  Sergiy Sukhanov; Laura Semprun-Prieto; Tadashi Yoshida; A Michael Tabony; Yusuke Higashi; Sarah Galvez; Patrice Delafontaine
Journal:  Am J Med Sci       Date:  2011-08       Impact factor: 2.378

7.  Angiotensin type 2 receptor signaling in satellite cells potentiates skeletal muscle regeneration.

Authors:  Tadashi Yoshida; Tashfin S Huq; Patrice Delafontaine
Journal:  J Biol Chem       Date:  2014-08-11       Impact factor: 5.157

8.  Angiotensin II inhibits satellite cell proliferation and prevents skeletal muscle regeneration.

Authors:  Tadashi Yoshida; Sarah Galvez; Sumit Tiwari; Bashir M Rezk; Laura Semprun-Prieto; Yusuke Higashi; Sergiy Sukhanov; Zipora Yablonka-Reuveni; Patrice Delafontaine
Journal:  J Biol Chem       Date:  2013-07-06       Impact factor: 5.157

9.  An Intronic Enhancer Element Regulates Angiotensin II Type 2 Receptor Expression during Satellite Cell Differentiation, and Its Activity Is Suppressed in Congestive Heart Failure.

Authors:  Tadashi Yoshida; Patrice Delafontaine
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

Review 10.  Cachexia in chronic heart failure: endocrine determinants and treatment perspectives.

Authors:  Norman Mangner; Yae Matsuo; Gerhard Schuler; Volker Adams
Journal:  Endocrine       Date:  2012-08-19       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.